1325.3000 -0.80 (-0.06%)
NSE Jun 20, 2025 15:31 PM
Volume: 1.8M
 

1325.30
-0.06%
Axis Direct
10% QoQ improvement in US sales (led by gRenvela) was a positive, however adj. EBITDA margin at 18.2% (down 475 bps YoY/ 50 bps QoQ) was below our expectation. Management expects pricing pressure in US to continue given channel consolidation and increased competition.
Dr. Reddy's Laboratories Ltd. is trading above all available SMAs
More from Dr. Reddy's Laboratories Ltd.
Recommended